Literature DB >> 22783327

Phosphatonins: physiological role and pathological changes.

Loredana Cavalli1, Celestina Mazzotta, Maria Luisa Brandi.   

Abstract

Maintenance of proper serum phosphate concentrations is required for healthy life, and critical for normal skeletal development and integrity. Several hormones and regulatory factors such as vitamin D, parathyroid hormone (PTH), and the phosphatonins (FGF-23, sFRP-4, MEPE) among others, may play a role only in the long-term regulation of phosphorus homeostasis.FGF23 is part of a previously unrecognized hormonal bone-parathyroid-kidney axis. Its synthesis and secretion by osteocytes are positively regulated by 1,25(OH)2D and serum phosphorus and negatively by the phosphate-regulating gene with homologies to endopeptidases on the X chromosome (PHEX), and the enzyme N-acetyl galactosamine trasferase 3 (PPGGalNacT3), encoded by GALnT3 gene, prevents its degradation.FGF23 requires Klotho protein as a coreceptor for high affinity binding to cognate FGF receptors (FGFRs). Mutations of any of FGF23, Klotho or GALnT3 genes can lead to a syndrome characterized by hyperphosphatemia, ectopic calcifications and recurrent long bone lesions with hyperostosis. Phosphatonin have been shown to be implicated in several common diseases involving kidney and mineral metabolism. FGF23 might also represent a promising putative marker for bone healing.

Entities:  

Keywords:  ADHR; FGF-23; GALnT3; Klotho; MEPE; PHEX; XLH; phosphate metabolism; phosphatonins; sFRP-4

Year:  2012        PMID: 22783327      PMCID: PMC3392670     

Source DB:  PubMed          Journal:  Clin Cases Miner Bone Metab        ISSN: 1724-8914


  42 in total

1.  Evidence for a bone-kidney axis regulating phosphate homeostasis.

Authors:  L Darryl Quarles
Journal:  J Clin Invest       Date:  2003-09       Impact factor: 14.808

2.  Human fibroblast growth factor-23 mutants suppress Na+-dependent phosphate co-transport activity and 1alpha,25-dihydroxyvitamin D3 production.

Authors:  Hitoshi Saito; Kenichiro Kusano; Masahiko Kinosaki; Hirotaka Ito; Michinori Hirata; Hiroko Segawa; Ken-Ichi Miyamoto; Naoshi Fukushima
Journal:  J Biol Chem       Date:  2002-11-04       Impact factor: 5.157

3.  Mutation of the mouse klotho gene leads to a syndrome resembling ageing.

Authors:  M Kuro-o; Y Matsumura; H Aizawa; H Kawaguchi; T Suga; T Utsugi; Y Ohyama; M Kurabayashi; T Kaname; E Kume; H Iwasaki; A Iida; T Shiraki-Iida; S Nishikawa; R Nagai; Y I Nabeshima
Journal:  Nature       Date:  1997-11-06       Impact factor: 49.962

4.  Autosomal-dominant hypophosphatemic rickets (ADHR) mutations stabilize FGF-23.

Authors:  K E White; G Carn; B Lorenz-Depiereux; A Benet-Pages; T M Strom; M J Econs
Journal:  Kidney Int       Date:  2001-12       Impact factor: 10.612

5.  Mediation of unusually high concentrations of 1,25-dihydroxyvitamin D in homozygous klotho mutant mice by increased expression of renal 1alpha-hydroxylase gene.

Authors:  Toru Yoshida; Toshihiko Fujimori; Yo-Ichi Nabeshima
Journal:  Endocrinology       Date:  2002-02       Impact factor: 4.736

6.  Autosomal dominant hypophosphataemic rickets is associated with mutations in FGF23.

Authors: 
Journal:  Nat Genet       Date:  2000-11       Impact factor: 38.330

7.  Identification of a novel fibroblast growth factor, FGF-23, preferentially expressed in the ventrolateral thalamic nucleus of the brain.

Authors:  T Yamashita; M Yoshioka; N Itoh
Journal:  Biochem Biophys Res Commun       Date:  2000-10-22       Impact factor: 3.575

8.  FGF23 is a putative marker for bone healing and regeneration.

Authors:  Sascha Goebel; Jasmin Lienau; Ulrich Rammoser; Lothar Seefried; Karl Florian Wintgens; Jochen Seufert; Georg Duda; Franz Jakob; Regina Ebert
Journal:  J Orthop Res       Date:  2009-09       Impact factor: 3.494

9.  Mutant FGF-23 responsible for autosomal dominant hypophosphatemic rickets is resistant to proteolytic cleavage and causes hypophosphatemia in vivo.

Authors:  Takashi Shimada; Takanori Muto; Itaru Urakawa; Takashi Yoneya; Yuji Yamazaki; Katsuya Okawa; Yasuhiro Takeuchi; Toshiro Fujita; Seiji Fukumoto; Takeyoshi Yamashita
Journal:  Endocrinology       Date:  2002-08       Impact factor: 4.736

10.  Phosphate provides an extracellular signal that drives nuclear export of Runx2/Cbfa1 in bone cells.

Authors:  T Fujita; N Izumo; R Fukuyama; T Meguro; H Nakamuta; T Kohno; M Koida
Journal:  Biochem Biophys Res Commun       Date:  2001-01-12       Impact factor: 3.575

View more
  4 in total

Review 1.  The rachitic tooth.

Authors:  Brian L Foster; Francisco H Nociti; Martha J Somerman
Journal:  Endocr Rev       Date:  2013-12-04       Impact factor: 19.871

2.  Treating osteoporosis: a near miss in an unusual case of FGF-23 mediated bone loss.

Authors:  Jinson Paul; Kripa Elizabeth Cherian; Nitin Kapoor; Thomas Vizhalil Paul
Journal:  BMJ Case Rep       Date:  2019-03-16

3.  A Case of Hyperphosphatemia and Elevated Fibroblast Growth Factor 23: A Brief Review of Hyperphosphatemia and Fibroblast Growth Factor 23 Pathway.

Authors:  Joseph Wang; Beth Vogt; Sidharth Kumar Sethi; Matthew G Sampson; Virginia Vega-Warner; Edgar A Otto; Rupesh Raina
Journal:  Kidney Int Rep       Date:  2017-05-17

4.  Adult-onset hypophosphatemic osteomalacia associated with Sjogren syndrome: Clinical case report.

Authors:  Guohua Shen; Yuwei Zhang; Shuang Hu; Bin Liu; Anren Kuang
Journal:  Medicine (Baltimore)       Date:  2017-03       Impact factor: 1.889

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.